Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.71−0.32 (-7.94%)
Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%
Oramed Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Oramed Pharmaceuticals's total assets was $400.92M at Sep 30, 2026. For fiscal 2025 it was $230.86M, up 48.7% from the year before. Over ten years it grew 26.6% a year on average. The highest annual figure on record is $230.86M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $230.86M | +48.7% |
| FY2024 | Dec 31, 2024 | $155.28M | -29.6% |
| FY2023 | Dec 31, 2023 | $220.55M | +72.3% |
| FY2021 | Aug 31, 2021 | $128.00M | +186.8% |
| FY2020 | Aug 31, 2020 | $44.63M | +28.8% |
| FY2019 | Aug 31, 2019 | $34.66M | -26.9% |
| FY2018 | Aug 31, 2018 | $47.40M | +22.4% |
| FY2017 | Aug 31, 2017 | $38.71M | -9.6% |
| FY2016 | Aug 31, 2016 | $42.83M | +62.5% |
| FY2015 | Aug 31, 2015 | $26.35M | +20.9% |
| FY2014 | Aug 31, 2014 | $21.80M | +151.8% |
| FY2013 | Aug 31, 2013 | $8.66M | +63.6% |
| FY2012 | Aug 31, 2012 | $5.29M | +22.4% |
| FY2011 | Aug 31, 2011 | $4.33M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Sep 30, 2026 | $400.92M | +81.8% |
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $369.64M | +128.6% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $268.85M | +82.2% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $230.86M | +48.7% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $220.49M | +33.6% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $161.68M | -12.2% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $147.54M | -27.6% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $155.28M | -29.6% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $165.08M | -28.5% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $184.22M | +17.9% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $203.65M | +27.5% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $220.55M | +72.3% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $230.89M | +186.9% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $156.31M | +153.5% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $159.78M | +290.0% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $128.00M | +186.8% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $80.49M | +74.4% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $61.66M | +106.3% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $40.97M | +31.6% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $44.63M | +28.8% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $46.16M | +23.3% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $29.88M | -28.5% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $31.14M | -34.3% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $34.66M | +0.0% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $37.43M | -2.1% |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | $41.81M | +0.6% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $47.40M | +22.4% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $34.66M | -12.9% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $38.25M | -8.6% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $41.54M | -7.5% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $38.71M | -9.6% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $39.79M | +9.6% |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $41.84M | +9.0% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $44.93M | +88.1% |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $42.83M | +62.5% |
| Q3 FY2016CQ2 2016 | May 31, 2016 | $36.31M | +64.1% |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $38.37M | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | $23.88M | – |
| Q4 FY2015CQ3 2015 | Aug 31, 2015 | $26.35M | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | $22.13M | – |
See a number that looks wrong?